Overview of phase I studies of intravenous administration of PV701, an oncolytic virus
/in International Publications, Newcastle Disease Virus /von 2003-12-01 / Curr. Opin. Mol. Ther. 2003 Dec;5(6):618-24Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2003-12-01 / Hum. Cell 2003 Dec;16(4):175-82[Antiviral effect of human CTLs activated by HBsAg stimulated dendritic cells in vitro]
/in Chronic Virus Hepatitis, International Publications /von 2003-12-01 / Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2003 Dec;17(4):365-8
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution